Shares of GW Pharmaceuticals Plc (GWPH) Sees Large Inflow of Net Money Flow

GW Pharmaceuticals Plc (GWPH) : $1.18 million worth of transactions were on upticks in GW Pharmaceuticals Plc (GWPH), compared to $0.07 million on downticks. The ratio between the two was 18.07, whereas, the net money flow stood at a healthy $1.12 million on Fridays session. The consistent buying on upticks in the stock accounted for $0million worth of trades. The total money flow into the stock stood at $0 million. The bulls and the bears were in an equilibrium as the stock closed with a loss of -0.28%. The stock was trading at $93.49, with a drop of $0.26 over the previous days close. The stock recorded 3.43% for the week.


GW Pharmaceuticals Plc (GWPH) : 6 investment research analysts covering GW Pharmaceuticals Plc (GWPH) have an average price target of $134.67 for the near short term. The highest target price given by the Brokerage Firm to the stock is $181 and the lowest target is $40 for the short term. Analysts expect the variance to be within $48.78 of the average price.

GW Pharmaceuticals Plc (NASDAQ:GWPH): stock turned positive on Friday. Though the stock opened at $94, the bulls momentum made the stock top out at $95.37 level for the day. The stock recorded a low of $93.01 and closed the trading day at $94.68, in the green by 0.99%. The total traded volume for the day was 236,515. The stock had closed at $93.75 in the previous days trading.

GW Pharmaceuticals plc is a United Kingdom-based biopharmaceutical company. The Company is engaged developing a portfolio of cannabinoid medicines, including Sativex for the treatment of multiple sclerosis spasticity and cancer pain, and Epidiolex for the treatment of childhood epilepsy. The Company also engaged in developing cannabinoids, medicines containing controlled substances, as well as plant-based prescription pharmaceutical products. The Companys product, Sativex is approved in 27 countries and is used as a treatment for symptom improvement in patients with moderate to severe spasticity due to multiple sclerosis (MS). The Sativex is also in Phase III clinical development for the treatment of cancer pain, the indication for the United States market.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.